127 related articles for article (PubMed ID: 15332420)
1. Systematic review of bisphosphonates for hypercalcaemia of malignancy.
Saunders Y; Ross JR; Broadley KE; Edmonds PM; Patel S;
Palliat Med; 2004 Jul; 18(5):418-31. PubMed ID: 15332420
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the role of bisphosphonates in metastatic disease.
Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
[TBL] [Abstract][Full Text] [Related]
3. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
Zojer N; Keck AV; Pecherstorfer M
Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
[TBL] [Abstract][Full Text] [Related]
4. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
6. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
7. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
[TBL] [Abstract][Full Text] [Related]
10. New bisphosphonates in the treatment of bone diseases.
Gatti D; Adami S
Drugs Aging; 1999 Oct; 15(4):285-96. PubMed ID: 10582775
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia.
Matsumoto T; Nagata N; Horikoshi N; Adachi I; Ohashi Y; Ogata E
J Int Med Res; 2002; 30(3):230-43. PubMed ID: 12166339
[TBL] [Abstract][Full Text] [Related]
13. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Wimalawansa SJ
Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates: biological response modifiers in breast cancer.
Paterson AH
Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
[TBL] [Abstract][Full Text] [Related]
16. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
17. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
Mallik S; Mallik G; Macabulos ST; Dorigo A
Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
19. Pamidronate.
Kellihan MJ; Mangino PD
Ann Pharmacother; 1992 Oct; 26(10):1262-9. PubMed ID: 1421653
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]